This page contains a Flash digital edition of a book.
gineco
ro
obstetrică
Alt studiu, efectuat pe piese rezecate cu supresia potenţialului proliferativ centului celulelor apoptozo-pozitive şi
de la paciente care au urmat preoperator caracterizată printr-o reducere a pro- expresiei Fas/ligandului Fas sunt obţinute
tratament cu agonişti, consideră apoptoza centului celulelor PCNA pozitive şi o după minimum 4 zile de la iniţierea
ca fiind un rezultat al tratamentului
(10)
. creştere a procentului celulelor apop- tratamentului. În concluzie, agoniştii
Tratamentul cu GnRH conduce la o tozo-pozitive. GnRH creşte expresia GnRH inhibă direct creşterea celulelor
scădere a numărului de celule miomatoase Fas şi induce expresia ligandului Fas în miomatoase prin supresia proliferării ce-
în cultură într-o manieră dependentă de culturile de celule miomatoase. GnRH lulare şi inducerea apoptozei, care poate
doză comparativ cu culturile de control. asupra numărului de celule miomatoase, fi asociată cu creşterea expresiei Fas şi
Inhibiţia creşterii celulare a fost asociată procentului celulelor PCNA pozitive, pro- inducerea expresiei ligandului Fas
(27)
.
Bibliografie selectivă
1. Abulafia O, et al. Effect of gonadotropin-releasing hormone agonist 16. Nisolle M, et al. Immunohistochemical study of the proliferation
treatment upon angiogenesis in uterine leiomyoma. Gynecol Ob- index, oestrogen receptors and progesterone receptors A and B in
stet Invest, 2001, 52(2): 108-13; leiomyomata and normal myometrium during the menstrual cy-
2. Aleem F, Predanic M. The hemodynamic effect of GnRH agoniste cle and under gonadotrophin-releasing hormone agonist therapy.
therapy on uterine leiomyoma vascularity: a prospective study us- Hum Reprod. 1999, 14(11): 2844-50;
ing transvaginal color Doppler sonography. Gynecol Endocrinol, 17. Rein MS, et al. Progesterone: a critical role in the pathogenesis of
1995, 9(3): 253-8; uterine myomas. Am J Obstet Gynecol, 1995, 172: 14-8;
3. Chegini N, et al. Gonadotrophin-releasing hormone (GnRH) and 18. Sharara F, Nieman L. Growth hormone receptor messenger ribo-
GnRH receptor gene expression in human myometrium and leio- nucleic acid exprssion in leiomyoma and surrounding myome-
myomata and the direct action af GnRH analogs on myometrial trium. Am J Obstet Gynecol. 1995, 173(3): 814-9;
smooth muscle cells and interaction with ovarian steroids in vitro. 19. Shozu M, et al. Inhibition of in situ expression of aromatase P450
J Clin Endocrinol Metab, 1996, 81(9): 3215-21; in leiomyoma of the uterus by leuprolin acetate. J Clin Endocrinol
4. Cheng Y, et al. Oestrogen deficiency causes DNA damage in uterine Metab. 2001, 86(11): 5405-11;
leiomyoma cells: a possible mechanism for shrinkage of fibroids by 20. Sozen I, et al. Effect o gonadotropin-relesing hormone agonists
GnRH agonists. BJOG, 2001, 108: 95-102; on monocyte chemotactic protein-1 production and macro-
5. Deligdisch L, et al. Pathologic changes in gonadotropin releasing phage infiltration in leiomyomatous uterus. Fertil Steril. 2001,
hormone agonist analogue treated uterine leiomyomata. Fertil 76(4): 792-6;
Steril, 1997, 67(5): 837-41; 21. Takahashi K, et al. Association of the shrinkage of uterine leio-
6. Di Lieto A, et al. Relationship between platelet-derived growth fac- myoma treated with GnRH agonist and deletion of long arm of
tor expression in leiomyomas and uterine volume changes after chromosome 7. Int J Oncol, 2001, 18(6): 1259-63;
gonadotropin-releasing hormone agonist treatment. Hum Pathol, 22. Takahashi K, et al. Value of magnetic resonace imaging in predict-
2002, 33(2): 220-4; ing efficacy of GnRH analogue treatment for uterinr leiomyoma.
7. Dou Q, et al. Suppression of transforming growth-factor beta (TGF Hum Reprod. 2001, 16(19): 1989-94;
beta) and TGF beta teceptor messenger ribonucleic acid and pro- 23. Van de Ven J, et al. Differential effect of gonadotropin-releasing
tein expression in leiomyomata in women receiving gonadotro- hormone analogue treatemtn on estrpgen levels and sulfatase ac-
phin-releasing hormone agonist therapy. J Clin Endocrinol Metab, tivity in uterine leiomyoma and myometrium. Fertil Steril, 2002,
1996, 81(9): 3222-30; 77(6): 1227-32;
8. Englund K, et al. Gene expression and tissue concentrations of 24. Van de Ven, et al. Levels of estrogen and progesterone receptors
IGF-I in human myometrium and fibroids under different hor- in the myometrium and leiomyoma tissue after suppression of
monal conditions. Mol Hum Reprod, 2000, 6(10): 915-20; estrogens with gonadotropin releasing hormone analogs. Gyne-
9. Gokdeniz R, et al. GnRH agonist decreases endothelial nitric oxide col Endocrinol, 2001, 15 Suppl, 6: 61-8;
synthase (eNOS) expression in leiomyoma. Int J Gynecol Obstet. 25. Vu K, et al. Cellular proliferation, estrogen receptor, progesterone
200, 70(3): 347-52; receptor, and bcl-2 expression in GnRH agonist-treated uterine
10. Higashijima T, et al. Gonadotroin-releasing hormone agonsite leiomyomas. Hum Pathol. 1998, 29(4): 359-63;
therapy induces apoptosis in uterine leiomyoma. Eur J Obstet 26. Wang H, et al. Different expression of estrogen receptors alpha
Gynecol Reprod Biol, 1996, 68: 169-73; and beta in human myometrium and leiomyoma during the
11. Huang S, et al. Enhanced deoxyribonucleic acid damage and proliferative phase of the menstrual cycle and after GnRHa treat-
repair but unchanged apoptosis in uterine leiomyomas treated ment. Gynecol Endocrinol. 2001, 15(6): 443-52;
with gonadotrophin-releasing hormone agonist. Am J Obstet Gy- 27. Wang Y, et al. Down-regulation of proliferation and up-regulation
necol, 1997, 177: 417-24; of apoptosis by gonadotrophin-releasing hormone agonist in cul-
12. Huang SC, et al. Fas and its ligands, caspases, and bcl-2 expres- tured leiomyoma cells. Eur J Endocrinol, 2002, 146(3): 447-56;
sion in gonadotropin-releasing hormone agonist-treated uterine 28. Yamamoto H, et al. Involvement of annexin V in the antiprolif-
leiomyoma. J Clin Endocrinol Metab, 2002, 87(10): 4580-6; erative effect of GnRH agonist on cultured human uterine leio-
13. Ito F, et al. Ultrastructural comparison of uterine leiomyoma cells myoma cells. Mol Hum Reprod, 2001, 7(2): 169-73;
from the same myoma nodule before and after gonadotropin- 29. Zhonghua Y, et al. Uterine myoma after cessation of gonadotro-
releasing hormone agonist treatment. Fertil Steril. 2001, 75(1): phin-releasing hormone agonist: ultrasound and histopatholoic
125-30; findings. Zhonghua Yi Xue Za Zi, 1998, 61(11): 625-9;
14. Kalir T, et al. Morphometric and electron microscopic analyses of 30. Tsutsumi M, et al. Translational regulation of the gonadotropin-
the effect of gonadotropin-releasing hormone agonist treatment releasing hormone receptor in alpha T3-1 cellsEndocrinology, Vol
on arteriole size in uterine leiomyomas. Arch Pathol Lab Med. 136, 1128-1136
2000, 124(9): 1295-8; 31. Mason DR, et al Homologous down-regulation of gonadotropin-
15. Mesia A, Popiolek D. Effects of gonadotropin-releasing hormone releasing hormone receptor sites and messenger ribonucleic acid
agonists on leiomyomas. Arch Patol Lab Med. 1999, 123(4): 282- transcripts in alpha T3-1 cells. Endocrinology, Vol 135, 1165-1170,
3; Copyright © 1994 by Endocrine Society
pag. 190 Vol. 4, Nr. 3 /septembrie 2008
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68
Produced with Yudu - www.yudu.com